发布求助
文献互助 智能选刊 最新文献

Cancer treatment reports最新文献

筛选
英文 中文
Phase II trial of combined 5-fluorouracil plus doxorubicin plus cisplatin (FAP regimen) in advanced gastric carcinoma. 5-氟尿嘧啶+阿霉素+顺铂(FAP方案)联合治疗晚期胃癌的II期临床试验。
Cancer treatment reports Pub Date : 1987-12-01
P Rougier, J P Droz, C Theodore, G Piot, P Herait, P Ruffie, P Carde, E Cvitkovic
{"title":"Phase II trial of combined 5-fluorouracil plus doxorubicin plus cisplatin (FAP regimen) in advanced gastric carcinoma.","authors":"P Rougier, J P Droz, C Theodore, G Piot, P Herait, P Ruffie, P Carde, E Cvitkovic","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 12","pages":"1301-2"},"PeriodicalIF":0.0,"publicationDate":"1987-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14810303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment evaluation in active control studies. 主动对照研究中的治疗评价。
Cancer treatment reports Pub Date : 1987-11-01
T R Fleming
{"title":"Treatment evaluation in active control studies.","authors":"T R Fleming","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 11","pages":"1061-5"},"PeriodicalIF":0.0,"publicationDate":"1987-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14249806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Facilitation of emergence of multidrug-resistant state by alteration of tumor environment: implications from competitive ecology models. 通过改变肿瘤环境促进多药耐药状态的出现:来自竞争生态模型的影响。
Cancer treatment reports Pub Date : 1987-11-01
S Michelson
{"title":"Facilitation of emergence of multidrug-resistant state by alteration of tumor environment: implications from competitive ecology models.","authors":"S Michelson","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The presence of multidrug-resistant (MDR) cells in a solid tumor constitutes a major problem in cancer therapy. Current thinking suggests that the resistant phenotype arises de novo during the tumor's evolution via somatic mutation mechanisms. The proportion of MDR cells, once established, may be enriched during therapy as a consequence of differential cell kill. Michelson et al have developed mathematical models of these phenomena to gain an insight into the dynamics of clonal subpopulation emergence in general and MDR emergence in particular, and I now show that one unexpected consequence of therapy may be the facilitation of MDR emergence due to damage inflicted on the host. The therapeutic damage to the host is modeled as a decreased ability to carry a specific tumor burden.</p>","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 11","pages":"1093-4"},"PeriodicalIF":0.0,"publicationDate":"1987-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14797481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral urea in treatment of liver metastases from colorectal adenocarcinoma. 口服尿素治疗结直肠腺癌肝转移。
Cancer treatment reports Pub Date : 1987-11-01
L Levin, W Kocha, A Driedger
{"title":"Oral urea in treatment of liver metastases from colorectal adenocarcinoma.","authors":"L Levin,&nbsp;W Kocha,&nbsp;A Driedger","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 11","pages":"1119"},"PeriodicalIF":0.0,"publicationDate":"1987-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14797482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase II trial of bisantrene in hepatocellular carcinoma: a Southwest Oncology Group Study. 双戊二烯治疗肝细胞癌的II期临床试验:西南肿瘤组研究。
Cancer treatment reports Pub Date : 1987-11-01
T D Brown, T R Fleming, R A Shildt, J D Cowan
{"title":"Phase II trial of bisantrene in hepatocellular carcinoma: a Southwest Oncology Group Study.","authors":"T D Brown,&nbsp;T R Fleming,&nbsp;R A Shildt,&nbsp;J D Cowan","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 11","pages":"1101-2"},"PeriodicalIF":0.0,"publicationDate":"1987-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13962083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pediatric phase I trial of carboplatin: a Childrens Cancer Study Group report. 卡铂的儿科I期试验:儿童癌症研究小组报告。
Cancer treatment reports Pub Date : 1987-11-01
P S Gaynon, L J Ettinger, D Moel, S E Siegel, E S Baum, W Krivit, G D Hammond
{"title":"Pediatric phase I trial of carboplatin: a Childrens Cancer Study Group report.","authors":"P S Gaynon,&nbsp;L J Ettinger,&nbsp;D Moel,&nbsp;S E Siegel,&nbsp;E S Baum,&nbsp;W Krivit,&nbsp;G D Hammond","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Carboplatin is one of a series of cisplatin analogs now undergoing clinical investigation. Phase I and II trials in adults demonstrate activity in a number of human cancers and less toxicity than might be expected with the parent compound. This phase I trial was undertaken to establish the maximum tolerated dose and the recommended phase II dose in children treated by a 1-hour iv infusion every 4 weeks. Twenty-nine patients with recurrent or progressive tumor were entered in this study at the Children's Hospital of Los Angeles and Children's Memorial Hospital in Chicago between April 12, 1983, and November 27, 1984. Beginning with a dose of 350 mg/m2 (about 80% of the adult phase II dose), we escalated the dose in groups of patients to 670 mg/m2; dose-limiting myelosuppression was encountered at this dose. Fifty-seven infusions are at least partially evaluable for toxicity. Asymptomatic hypomagnesemia, hypocalcemia, and ototoxicity were observed infrequently, and nausea and vomiting were mild. One patient with a mixed glioma of the posterior fossa achieved a good partial response lasting 9 months. Stable disease for greater than or equal to 6 months was observed in three patients: one each with ependymoma, brain stem glioma, and spinal cord astrocytoma. The recommended pediatric phase II dose is 560 mg/m2 given as a 1-hour iv infusion every 4 weeks.</p>","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 11","pages":"1039-42"},"PeriodicalIF":0.0,"publicationDate":"1987-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14442798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase II trial of diaziquone in patients with refractory and relapsing multiple myeloma: a Southwest Oncology Group Study. 在难治性和复发性多发性骨髓瘤患者中使用地齐酮的II期试验:一项西南肿瘤组研究。
Cancer treatment reports Pub Date : 1987-11-01
W J Stuckey, J Crowley, L H Baker, N R Larrimer, K H Hanson, J D Bonnet, L A White
{"title":"Phase II trial of diaziquone in patients with refractory and relapsing multiple myeloma: a Southwest Oncology Group Study.","authors":"W J Stuckey,&nbsp;J Crowley,&nbsp;L H Baker,&nbsp;N R Larrimer,&nbsp;K H Hanson,&nbsp;J D Bonnet,&nbsp;L A White","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 11","pages":"1095-6"},"PeriodicalIF":0.0,"publicationDate":"1987-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14249807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase II trial of ifosfamide/mesna in metastatic adult renal carcinoma. 异环磷酰胺/mesna治疗转移性成人肾癌的II期试验。
Cancer treatment reports Pub Date : 1987-11-01
A De Forges, J P Droz, M Ghosn, C Theodore
{"title":"Phase II trial of ifosfamide/mesna in metastatic adult renal carcinoma.","authors":"A De Forges,&nbsp;J P Droz,&nbsp;M Ghosn,&nbsp;C Theodore","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 11","pages":"1103"},"PeriodicalIF":0.0,"publicationDate":"1987-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14249808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ifosfamide/mesna and hematuria. Ifosfamide/mesna和血尿。
Cancer treatment reports Pub Date : 1987-11-01
C B Pratt, M P Goren
{"title":"Ifosfamide/mesna and hematuria.","authors":"C B Pratt,&nbsp;M P Goren","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 11","pages":"1124-5"},"PeriodicalIF":0.0,"publicationDate":"1987-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14251193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inadequacy of predicted creatinine clearance as guide to chemotherapy. 预测肌酐清除率作为化疗指导的不足。
Cancer treatment reports Pub Date : 1987-11-01
D F McDermott, A Galindo, R L Sherman, E A Jaffe, M Coleman, M W Pasmantier
{"title":"Inadequacy of predicted creatinine clearance as guide to chemotherapy.","authors":"D F McDermott,&nbsp;A Galindo,&nbsp;R L Sherman,&nbsp;E A Jaffe,&nbsp;M Coleman,&nbsp;M W Pasmantier","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Many chemotherapeutic agents are nephrotoxic and/or excreted via the kidney. Thus, careful evaluation of renal function is important since drug dosages are often lowered in patients with impaired renal function. When the creatinine clearance as calculated by the method of Cockcroft and Gault from the patient's age, weight, and serum creatinine was compared to the measured creatinine clearance in the same patients, the correlation coefficient was low (r = 0.40) and the average difference between the predicted and measured creatinine clearance values was 25.3%. Thus, in our patient population, creatinine clearance calculated by the method of Cockcroft and Gault did not correlate well with measured creatinine clearance and thus was not useful as a clinical tool.</p>","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 11","pages":"1067-9"},"PeriodicalIF":0.0,"publicationDate":"1987-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14796897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信